INDICATIONS

REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

THE NEED FOR REBLOZYL: REBLOZYL MECHANISM OF ACTION

ESA versus REBLOZYL® erythroid maturation ESA versus REBLOZYL® erythroid maturation

ESA=erythropoiesis-stimulating agent.

Erythroid and arrow icon

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

  • REBLOZYL binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7
  • In preclinical models, REBLOZYL improved1,8:
    • Hgb levels
    • RBC morphology
    • Other hematology parameters* associated with ineffective erythropoiesis

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin; RBC=red blood cell; TGF-beta=transforming growth factor beta.

THE NEED FOR REBLOZYL: REBLOZYL MECHANISM OF ACTION

ESA versus REBLOZYL® erythroid maturation ESA versus REBLOZYL® erythroid maturation

ESA=erythropoiesis-stimulating agent.

Erythroid and arrow icon

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

  • REBLOZYL binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7
  • In preclinical models, REBLOZYL improved1,8:
    • Hgb levels
    • RBC morphology
    • Other hematology parameters* associated with ineffective erythropoiesis

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin; RBC=red blood cell; TGF-beta=transforming growth factor beta.

References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2022. 2. Liang R, Ghaffari S. Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease. Br J Haematol. 2016;174(5):661-673. 3. Elliott S and Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics. 2012;6:163-189. 4. Elliott S, Phama E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol. 2008;36:1573-1584. 5. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022-2036. 6. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414. 7. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770. 8. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014;123(25):3864-3872.